Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026
NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...
clinical data
Advertisement
Galmed to Acquire Colospan in Major GI MedTech Expansion
RAMAT GAN, Israel – June 8, 2026 Galmed Pharmaceuticals has entered into a definitive agreement to acquire Colospan Ltd.,...
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Shattuck Labs to Present Phase 1 Data for SL-325 on June 8
AUSTIN, Texas and DURHAM, N.C., June 5, 2026 Shattuck Labs announced that it will host an investor call and...
STORM Therapeutics Reports Promising STC-15 Sarcoma Data at ASCO
CAMBRIDGE, UK, May 22, 2026 STORM Therapeutics announced that new Phase 1 data for its first-in-class METTL3 inhibitor STC-15...
Advertisements
ImmunityBio to Present ANKTIVA Data at AUA 2026
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
Keenova TERLIVAZ Real-World Data Advances HRS-AKI Care
Dublin, Ireland | May 1, 2026 Keenova Therapeutics has announced new real-world clinical analysis of TERLIVAZ® (terlipressin) for hepatorenal...
Roche ENSPRYNG Shows MOGAD Clinical Benefit Data
BASEL, Switzerland, April 2026 Roche reported new clinical findings demonstrating the effectiveness of ENSPRYNG® (satralizumab) in reducing relapse risk...
Monopar Reports Phase 3 ALXN1840 Data at AAN 2026
WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
Advertisement
